Richard S. Levy - 13 Nov 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Issuer symbol
MDGL
Transactions as of
13 Nov 2025
Net transactions value
-$4,311,038
Form type
4
Filing time
14 Nov 2025, 17:12:26 UTC
Previous filing
03 Jul 2025
Next filing
26 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Levy Richard S Director C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Mardi Dier, as Attorney-in-Fact 14 Nov 2025 0001454983

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $18,400 +2,500 +12% $7.36 23,697 13 Nov 2025 Direct
transaction MDGL Common Stock Options Exercise $98,760 +6,000 +25% $16.46 29,697 13 Nov 2025 Direct
transaction MDGL Common Stock Sale $75,142 -146 -0.49% $514.67 29,551 13 Nov 2025 Direct F1, F2
transaction MDGL Common Stock Sale $473,876 -919 -3.1% $515.64 28,632 13 Nov 2025 Direct F1, F3
transaction MDGL Common Stock Sale $333,796 -645 -2.3% $517.51 27,987 13 Nov 2025 Direct F1, F4
transaction MDGL Common Stock Sale $432,974 -835 -3% $518.53 27,152 13 Nov 2025 Direct F1, F5
transaction MDGL Common Stock Sale $704,147 -1,355 -5% $519.67 25,797 13 Nov 2025 Direct F1, F6
transaction MDGL Common Stock Sale $160,369 -308 -1.2% $520.68 25,489 13 Nov 2025 Direct F1, F7
transaction MDGL Common Stock Sale $570,836 -1,094 -4.3% $521.79 24,395 13 Nov 2025 Direct F1, F8
transaction MDGL Common Stock Sale $749,557 -1,434 -5.9% $522.70 22,961 13 Nov 2025 Direct F1, F9
transaction MDGL Common Stock Sale $424,687 -811 -3.5% $523.66 22,150 13 Nov 2025 Direct F1, F10
transaction MDGL Common Stock Sale $80,247 -153 -0.69% $524.49 21,997 13 Nov 2025 Direct F1, F11
transaction MDGL Common Stock Sale $63,202 -120 -0.55% $526.68 21,877 13 Nov 2025 Direct F1, F12
transaction MDGL Common Stock Sale $105,570 -200 -0.91% $527.85 21,677 13 Nov 2025 Direct F1, F13
transaction MDGL Common Stock Sale $232,586 -440 -2% $528.60 21,237 13 Nov 2025 Direct F1, F14
transaction MDGL Common Stock Sale $21,208 -40 -0.19% $530.21 21,197 13 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -2,500 -50% $0.000000 2,500 13 Nov 2025 Common Stock 2,500 $7.36 Direct F15
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -6,000 -60% $0.000000 4,000 13 Nov 2025 Common Stock 6,000 $16.46 Direct F15
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.03 to $514.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.19 to $516.10, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $517.15 to $518.10, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $518.155 to $519.04, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $519.18 to $520.15, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $520.21 to $521.18, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $521.22 to $522.21, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $522.30 to $523.29, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $523.31 to $524.29, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $524.31 to $524.71, inclusive.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.17 to $527.09, inclusive.
F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.17 to $528.15, inclusive.
F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.18 to $528.94, inclusive.
F15 The shares underlying this option are fully vested and exercisable.